Skip to main content

Advertisement

SpringerLink
Log in

Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS

An Overview and Methodological Discussion

  • Review Article
  • Opportunistic Infection Prophylaxis in AIDS
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Dramatic progress has recently been made in defining the pathogenesis and treatment of HIV infection. For the first time in the history of the AIDS epidemic, clinicians have at their disposal an understanding of the replication kinetics of HIV, reliable assays to measure viral load, an increasing number of effective agents to suppress viral replication and to reverse the process of immune system destruction, and a range of options for the treatment and prophylaxis of most of the major opportunistic infections in HIV disease. These remarkable advances are not without their costs, however. New antiretroviral therapies and opportunistic infection prophylaxis regimens impose considerable financial strain on public and private budgets for HIV patient care. They force decision-makers to confront a variety of competing considerations, including issues of length and quality of life, the risks of adverse effects and toxicities, and the dangers of promoting resistance.

Questions regarding the continued appropriateness and efficiency of opportunistic infection prevention have prompted increased interest in studies of the cost effectiveness of HIV patient care. In this article, we reviewed the literature on the economic evaluation of prophylaxis for HIV-related complications. Section 1 provides background on recent scientific and clinical advances. Section 2 reviews the state-of-the-art understanding of the cost effectiveness of prophylaxis against specific opportunistic infections. Section 3 broadens the discussion to consider the more general question of optimal allocation of prophylaxis resources across competing opportunistic infections. In Section 4, we briefly examined the influence of cost-effectiveness evaluations on the development and refinement of clinical guidelines for HIV-related opportunistic infection prevention in the US. Section 5 presents some of the methodological challenges that arise in applying the methods of cost-effectiveness analysis to the particular case of opportunistic infection prevention in AIDS. We close, in Section 6, with a comment on directions for further research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997: 46-RR12: 1–46

  2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997; 277: 1962–9

    Article  PubMed  CAS  Google Scholar 

  3. National ADAP monitoring project: interim technical report. Washington, DC: National Alliance of State and Territorial AIDS Directors and the AIDS Treatment Data Network, 1997

  4. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiencyvirus: disease-specific recommendations. Clin Infect Dis 1995; 21 Suppl. 1: 32–43

    Article  Google Scholar 

  5. Drug topics red book. Montvale (NJ): Medical Economics, 1996

  6. Seage GR, Landers S, Barry MA, et al. Medical care costs of AIDS in Massachusetts. JAMA 1986; 256: 3107–9

    Article  PubMed  Google Scholar 

  7. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987; 102: 5–17

    PubMed  CAS  Google Scholar 

  8. Hellinger FJ. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry 1992; 29 (3): 356–65

    PubMed  CAS  Google Scholar 

  9. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474–8

    Article  PubMed  CAS  Google Scholar 

  10. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr 1997; 14: 223–31

    Article  CAS  Google Scholar 

  11. Gable CB, Tierce JC, Simison D, et al. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr 1996; 12: 413–20

    Article  CAS  Google Scholar 

  12. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259: 1185–9

    Article  PubMed  CAS  Google Scholar 

  13. Freedberg KA, Tosteson ANA, Cohen CJ, et al. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/ul: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991; 4: 521–31

    PubMed  CAS  Google Scholar 

  14. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327: 1842–8

    Article  PubMed  CAS  Google Scholar 

  15. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA 1991; 266: 820–4

    Article  PubMed  CAS  Google Scholar 

  16. Freedberg KA, Hardy WD, Holzman RS, et al. Validating literature- based models with direct clinical trial results: the costeffectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making 1996; 16: 29–35

    Article  PubMed  CAS  Google Scholar 

  17. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335: 392–8

    Article  PubMed  CAS  Google Scholar 

  18. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384–90

    Article  PubMed  CAS  Google Scholar 

  19. Bozzette SA, Finklestein DM, Spector SA, et al. A randomised trial of 3 antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 693–9

    Article  PubMed  CAS  Google Scholar 

  20. Moore RM, Chaisson RE. Cost-effectiveness analysis for Mycobacterium avium complex disease. Am J Med 1997; 102: 50–5

    Article  Google Scholar 

  21. Freedberg KA, Cohen CJ, Barber TW. Preventing Mycobacterium avium complex infection in patients with AIDS: a costeffectiveness analysis. J Acquir Immune Defic Syndr 1997; 15: 275–82

    Article  CAS  Google Scholar 

  22. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 700–5

    Article  PubMed  CAS  Google Scholar 

  23. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of preventing fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997; 17: 373–81

    Article  PubMed  CAS  Google Scholar 

  24. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganiclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334: 1491–7

    Article  PubMed  CAS  Google Scholar 

  25. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1997; 16: 15–21

    Article  CAS  Google Scholar 

  26. Paltiel AD, Freedberg KA. Cost-effectiveness of preventing CMV disease in AIDS patients. Interfaces. In press

  27. Rose DN, Sacks HS, Lan V. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS 1997; 11: 883–7

    Article  PubMed  CAS  Google Scholar 

  28. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am J Med 1993: 942; 160–8

    Article  Google Scholar 

  29. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828–33

    Article  PubMed  CAS  Google Scholar 

  30. Benson CA, Cohn DL, Williams P, the ACTG 196/CPCRA 009 Study Team, et al. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA+RBT prevention of Mycobacterium avium Complex (MAC) disease in HIV+ patients with CD4 counts < 100 cells/ul. Third Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1; Washington, DC: 91

    Google Scholar 

  31. Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279: 130–6

    Article  PubMed  CAS  Google Scholar 

  32. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992; 6: 191–4

    Article  PubMed  CAS  Google Scholar 

  33. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. Ann Intern Med 1997; 126: 689–96

    PubMed  CAS  Google Scholar 

  34. Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals: Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998; 12 (3): 269–77

    Article  PubMed  CAS  Google Scholar 

  35. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/IDS guidelines for prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997; 25 Suppl. 3: S299–312

    Google Scholar 

  36. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–33

    Article  PubMed  CAS  Google Scholar 

  37. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. Pharmacoeconomics 1996; 10 (2): 109–13

    Article  PubMed  CAS  Google Scholar 

  38. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081–90

    Article  PubMed  CAS  Google Scholar 

  39. Delta Coordinating Committee. Delta: a randomized doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283–91

    Article  Google Scholar 

  40. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–33

    Article  PubMed  CAS  Google Scholar 

  41. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago

    Google Scholar 

  42. Kaplan JE, Masur H, Jaffe HW, et al. Preventing opportunistic infections in persons infected with HIV: guidelines [editorial]. JAMA 1997; 278 (4): 337–8

    Article  PubMed  CAS  Google Scholar 

  43. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effort of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997; 277 (19): 1519–20

    Article  PubMed  CAS  Google Scholar 

  44. AIDS Clinical Trial Group Protocol 362. A randomized, placebo controlled trial to determine the efficacy of azithromycin prophylaxis for the primary prevention of Mycobacterium avium complex (MAC) disease and other infections in subjects who have achieved an increase in CD4 cells on antiretroviral therapy. Version 1.0. Washington, DC: National Institute of Allergy and Infectious Diseases, 1997

    Google Scholar 

  45. Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996

  46. Owens DK, Nease RF, Harris RA. Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings [abstract]. Med Decis Making 1993; 13: 395

    Google Scholar 

  47. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research policy analysis. Health Psychol 1981; 1: 61–80

    Article  Google Scholar 

  48. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473–81

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Economics Research Unit, Section of General Internal Medicine and the Clinical AIDS Program, Department of Medicine and Evans Medical Foundation, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA

    Kenneth A. Freedberg

  2. Department of Epidemiology and Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA

    Kenneth A. Freedberg

  3. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut, USA

    A. David Paltiel

Authors
  1. Kenneth A. Freedberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. David Paltiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth A. Freedberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freedberg, K.A., Paltiel, A.D. Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS. Pharmacoeconomics 14, 165–173 (1998). https://doi.org/10.2165/00019053-199814020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199814020-00005

Keywords

Search

Navigation